FDA Issued Postmarket CVD Safety Warning for 1 in 4 Cancer Drugs
Many of these alerts occurred almost 5 after the drug approval, but the overall risk for a major cardiac event remains small, lead author says.
United States Vanderbilt University Ohio State University Daniel Addison Solove Research Institute Vanderbilt University Medical Center
Source: medscape.com